Sleeve gastrectomy for morbid obesity. Review uri icon

Overview

abstract

  • The rising prevalence of morbid obesity and the increased incidence of super-obese patients (BMI >50 kg/m2) seeking surgical treatments has led to the search for surgical techniques that provide adequate EWL with the least possible morbidity. Sleeve gastrectomy (SG) was initially added as a modification to the biliopancreatic diversion (BPD) and then combined with a duodenal switch (DS) in 1988. It was first performed laparoscopically in 1999 as part of a DS and subsequently done alone as a staged procedure in 2000. With the revelation that patients experienced weight loss after SG, interest in using this procedure as a bridge to more definitive surgical treatment has risen. Benefits of SG include the low rate of complications, the avoidance of foreign material, the maintenance of normal gastro-intestinal continuity, the absence of malabsorption and the ability to convert to multiple other operations. Reduction of the ghrelin-producing stomach mass may account for its superiority to other gastric restrictive procedures. SG should be in the armamentarium of all bariatric surgeons. Nonetheless, long-term studies are necessary to see if it is a durable procedure in the treatment of morbid obesity.

publication date

  • July 1, 2007

Research

keywords

  • Gastrectomy
  • Obesity, Morbid

Identity

Scopus Document Identifier

  • 35748941268

Digital Object Identifier (DOI)

  • 10.1007/s11695-007-9151-x

PubMed ID

  • 17894158

Additional Document Info

volume

  • 17

issue

  • 7